Ligand Pharmaceuticals Incorporated LGND partner GlaxoSmithKline
GSK announced today that the U.S. Food and Drug Administration (FDA)
has approved PROMACTA for the treatment of thrombocytopenia (low blood
platelet counts) in patients with chronic hepatitis C to allow them to
initiate and maintain interferon-based therapy. PROMACTA is the first
supportive care treatment available to patients who are ineligible or poor
candidates for interferon-based therapy due to their low blood platelet
counts. PROMACTA in combination with interferon-based therapy has been shown
to improve a patient's chance of achieving a sustained virologic response
(SVR) or viral cure.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in